Altogether, these findings support the idea that a weak lifelong activation of the PLCG2 pathway may confer protection against AD, and pharmacological modulation of microglia via TREM2-PLCγ2 pathway-dependent stimulation may be a novel therapeutic option for the treatment of AD. This evidence concerns the gene PLCG2 and Alzheimer disease.